MTOR and nonpapillary renal cell carcinoma: In particular, advanced ccRCC is usually treated by targeted therapies or combination treatment including VEGF-TKIs, mTOR inhibitors, and immunotherapy, so the PDC/PDX models may exert advantages to investigate drug sensitivity and resistance against such treatments.